Rostec Developed the World's First Universal Bacteriophage Drug to Treat Infections

Rostec Developed the World's First Universal Bacteriophage Drug to Treat Infections

Microgen Scientific and Production Association of the National Immunobiological Company (Nacimbio) has developed a universal pharmaceutical product allowing only one capsule to replace an entire course of antimicrobial agents for treatment of infectious diseases. The drug selectively attacks bacterial cells, but not the entire human microbiota.

"This new drug has no counterparts in the entire world. One capsule includes an entire set of bacteriophages for prevention and treatment of a whole range of widespread diseases. The drug has already been developed and it will enter the market following the required tests and the state registration. As of today, the pre-clinical studies and phase 1 clinical trials have been successfully completed and the results demonstrated drug safety," noted Kirill Gaidash, General Director of NPO Microgen.

The Rostec's new product will enable treatment and prevention of diseases caused by bacteria of the genus of Staphylococcus, Streptococcus, Proteus - P. vulgaris, P. mirabilis, Klebsiella pneumoniae, as well as Pseudomonas aeruginosa and Escherichia coli.

These bacteria cause an entire range of otolaryngology diseases (tonsillitis, pharyngitis, laryngitis, tracheitis, bronchitis, pneumonia, pleuritis), surgical and urogenital infections (abscess, hidradenitis, paraproctitis, mastitis, osteomyelitis, cystitis, pyelonephritis, endometritis, etc.), various general sepsis conditions and pyoinflammatory diseases in new-born children.